Limits...
Henoch-Schönlein purpura in a renal transplant recipient with prior IgA nephropathy following influenza vaccination.

McNally A, McGregor D, Searle M, Irvine J, Cross N - Clin Kidney J (2013)

Bottom Line: The patient had prior end-stage renal failure (ESRF) secondary to IgAN, without clinical evidence of IgAN recurrence after transplantation.This is of clinical relevance as influenza vaccination is regarded safe, effective, and recommended after renal transplantation.Nephrologists should be aware of the potential for influenza vaccination to have adverse effects in renal transplant recipients, especially if the primary renal disease is HSP or IgAN.

View Article: PubMed Central - PubMed

Affiliation: Department of Nephrology , Christchurch Hospital, Canterbury District Health Board , Christchurch , New Zealand.

ABSTRACT
Henoch-Schönlein purpura (HSP) is a systemic small-vessel leucocytoclastic vasculitis with deposition of immune complexes containing Immunoglobulin A (IgA). IgA Nephropathy (IgAN) is a glomerulonephritis caused by mesangial deposition of IgA. The onset of HSP, but not IgAN, has been linked to influenza vaccination. We report the first case of HSP with glomerular involvement, in a renal transplant recipient following influenza vaccination. The patient had prior end-stage renal failure (ESRF) secondary to IgAN, without clinical evidence of IgAN recurrence after transplantation. This is of clinical relevance as influenza vaccination is regarded safe, effective, and recommended after renal transplantation. Nephrologists should be aware of the potential for influenza vaccination to have adverse effects in renal transplant recipients, especially if the primary renal disease is HSP or IgAN.

No MeSH data available.


Related in: MedlinePlus

Renal transplant biopsy—active IgA nephropathy with focal crescent formation.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4400476&req=5

SFT029F2: Renal transplant biopsy—active IgA nephropathy with focal crescent formation.

Mentions: Seven weeks after the onset of purpura, there was microscopic haematuria (50–100 × 106/L RBCs) which persisted for 6 months, along with the development of cellular casts, dysmorphic RBCs, nephrotic range proteinuria (urine TPCR 658.1 g/mol), oedema and worsening hypertension (148/96 mmHg). Renal function remained stable [creatinine 102 μmol/L, eGFR (MDRD) 50 mL/min/1.73 m2]. Allograft biopsy showed active IgAN, with focal cellular or fibrocellular crescents in 4 of 25 glomeruli (Figure 2), and moderate (2+) mesangial staining for IgA. There was minor interstitial fibrosis and no features of rejection.Fig. 2.


Henoch-Schönlein purpura in a renal transplant recipient with prior IgA nephropathy following influenza vaccination.

McNally A, McGregor D, Searle M, Irvine J, Cross N - Clin Kidney J (2013)

Renal transplant biopsy—active IgA nephropathy with focal crescent formation.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4400476&req=5

SFT029F2: Renal transplant biopsy—active IgA nephropathy with focal crescent formation.
Mentions: Seven weeks after the onset of purpura, there was microscopic haematuria (50–100 × 106/L RBCs) which persisted for 6 months, along with the development of cellular casts, dysmorphic RBCs, nephrotic range proteinuria (urine TPCR 658.1 g/mol), oedema and worsening hypertension (148/96 mmHg). Renal function remained stable [creatinine 102 μmol/L, eGFR (MDRD) 50 mL/min/1.73 m2]. Allograft biopsy showed active IgAN, with focal cellular or fibrocellular crescents in 4 of 25 glomeruli (Figure 2), and moderate (2+) mesangial staining for IgA. There was minor interstitial fibrosis and no features of rejection.Fig. 2.

Bottom Line: The patient had prior end-stage renal failure (ESRF) secondary to IgAN, without clinical evidence of IgAN recurrence after transplantation.This is of clinical relevance as influenza vaccination is regarded safe, effective, and recommended after renal transplantation.Nephrologists should be aware of the potential for influenza vaccination to have adverse effects in renal transplant recipients, especially if the primary renal disease is HSP or IgAN.

View Article: PubMed Central - PubMed

Affiliation: Department of Nephrology , Christchurch Hospital, Canterbury District Health Board , Christchurch , New Zealand.

ABSTRACT
Henoch-Schönlein purpura (HSP) is a systemic small-vessel leucocytoclastic vasculitis with deposition of immune complexes containing Immunoglobulin A (IgA). IgA Nephropathy (IgAN) is a glomerulonephritis caused by mesangial deposition of IgA. The onset of HSP, but not IgAN, has been linked to influenza vaccination. We report the first case of HSP with glomerular involvement, in a renal transplant recipient following influenza vaccination. The patient had prior end-stage renal failure (ESRF) secondary to IgAN, without clinical evidence of IgAN recurrence after transplantation. This is of clinical relevance as influenza vaccination is regarded safe, effective, and recommended after renal transplantation. Nephrologists should be aware of the potential for influenza vaccination to have adverse effects in renal transplant recipients, especially if the primary renal disease is HSP or IgAN.

No MeSH data available.


Related in: MedlinePlus